Paper Details

  1. Home
  2. Paper Details

Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy.

Author: BukowskiR M, CareyR W, CaseD C, FishkinE H, HenryD H, JacobsonR J, JonesS E, KellerA M, KuglerJ W, NicholsC R

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This report discusses the use of recombinant human erythropoietin (rHuEPO) to treat anemia in patients with advanced cancer, highlighting the potential benefits and safety of this treatment.
Paper Details　
Original Abstract of the Article :
Patients with advanced cancer frequently experience clinically significant anemia, which is often exacerbated by myelosuppressive chemotherapy. Consistent with the anemia of chronic disease, studies have documented serum erythropoietin levels that are inappropriately low for the degree of anemia in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jnci/85.10.801

データ提供：米国国立医学図書館（NLM）

Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients

Anemia, a condition where the body doesn't have enough red blood cells, can be a debilitating problem, especially for cancer patients undergoing chemotherapy. It's like a desert traveler struggling to make their way through the sand, lacking the energy to continue their journey.

This study investigates the use of recombinant human erythropoietin (rHuEPO), a medication that stimulates red blood cell production, in treating anemic cancer patients. It's like finding a magical elixir that replenishes the traveler's energy and strength.

Researchers found that rHuEPO was safe and effective in treating anemia in cancer patients. It's like giving the traveler a much-needed boost, allowing them to continue their journey with renewed vigor.

Improving Quality of Life: A New Era in Cancer Treatment

The study highlights the importance of treating anemia in cancer patients, improving their quality of life and overall well-being. It's like providing a safe haven for the traveler, ensuring that they have the energy and resources to complete their journey.

Addressing Anemia: A Comprehensive Approach to Cancer Care

This research emphasizes the importance of addressing anemia as part of comprehensive cancer care. It's like providing a variety of resources and support systems for the traveler, ensuring their safety and well-being throughout their journey.

Dr.Camel's Conclusion

This study demonstrates the effectiveness of rHuEPO in treating anemia in cancer patients, improving their quality of life and overall health. It's like finding a way to make the desert journey more manageable, providing the traveler with the strength and energy to continue their journey.

Date :
  1. Date Completed 1993-06-10
  2. Date Revised 2019-05-12
Further Info :

Pubmed ID

8487324

DOI: Digital Object Identifier

10.1093/jnci/85.10.801

Related Literature

Article Analysis
・Effective treatment of anemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.